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Background
Metastatic bladder cancer (MBC) is a relatively chemosen-
sitive neoplasm yet response durations are generally short-
lived. Recently, immune checkpoint blockade has demon-
strated unparalleled activity in heavily pre-treated patients
(pts) with MBC. The role of standard chemotherapy on
the immune system of patients with MBC, and optimal
approaches to combining chemotherapy and immune
checkpoint blockade, has not been comprehensively
explored.
Methods
Pts with MBC were enrolled on a Phase II trial of che-
motherapy + CTLA4 blockade. Patients received 2 cycles
of gemcitabine + cisplatin (GC) followed by 4 cycles of GC
+ ipilimumab (GCI). Flow cytometry was performed on
peripheral blood mononuclear cells at baseline, after GC,
and after GCI to determine the impact of treatment on
the frequency and phenotype of CD4+ and CD8+ T cells,
regulatory T cells (CD4+CD25+CD127-CD45RA-Tregs),
and myeloid-derived suppressor cells. Comparisons
between time-points were made using Wilcoxon’s rank
test. Plasma collected from patients was assayed for the
expression of 41 cytokines and chemokines by multiplex
assay at these same timepoints.
Results
The trial has completed enrollment (n=36) and flow cyto-
metry data are available for the complete treatment
sequence on 27 pts as of 5/2015 (Table). Hierarchical clus-
ter analysis of the cytokine/chemokine panel and
cellular immunophenotype demonstrated clustering of
post-GC alone specimens and post-GC + ipilimumab
specimens. The % of CD4+ and CD8+ T cells was signifi-




Baseline Post GC Post GC +
Ipi
Wilcoxon signed-rank text (p value)
Post-GC versus
Baseline
Post-GC + Ipi versus Post
GC
Post-GC + Ipi verus
Baseline
%CD3CD4 8.3 (5.5-13.10) 9.7 (5.1-16.4) 15.8 (9.4-27.0) 0.13 0.008 0.001
%CD3CD8 4.4 (2.6-6.7) 4.8 (3.1-7.6) 7.3 (4.2-13.5) 0.9 0.06 0.01
% Tregs 6.5 (4.1-7.4) 6.2 (5.2-8.8) 6.2 (4.4-8.0) 0.6 0.4 0.8
% Granulcytic
MDSC
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cantly increased after addition of ipilimumab. The level of
cytokines involved in proinflammatory and T cell activa-
tion such as IL-12, IL-7, IL-15, IFNg, IFNa and IL-1-a
and –ß was higher in the post-GC + ipilimumab than
those in post-GC.
Conclusions
Gemcitabine plus cisplatin alone did not demonstrate sig-
nificant favorable or unfavorable effects on the circulating
immunocytes profiled. The addition of ipilimumab
induced pharmacodynamic changes including an increase
in circulating CD4+ and CD8+ T cells and modulation of
the peripheral blood cytokine/chemokine milieu generally
suggestive of an immunostimulatory effect. The immuno-
modulatory effects of treatment, interpreted in the context
of the clinical outcome data, may help refine an under-
standing of the mechanistic basis of anticancer effects and
inform subsequent rational combinations of chemotherapy
plus immune checkpoint blockade.
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